Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

297.19USD
2 Dec 2016
Change (% chg)

$1.41 (+0.48%)
Prev Close
$295.78
Open
$296.53
Day's High
$299.95
Day's Low
$293.04
Volume
1,429,360
Avg. Vol
1,626,213
52-wk High
$333.65
52-wk Low
$223.02

Select another date:

Wed, Nov 23 2016

Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks

NEW YORK Eli Lilly & Co's massive setback for its experimental Alzheimer's disease treatment on Wednesday sent investors scrambling to re-evaluate shares of the U.S. drugmaker and those of companies making competing therapies, including biotech stalwart Biogen Inc.

BRIEF-Biogen announces additional members of management team of hemophilia spin-off company Bioverativ

* Biogen Inc - Appoints Rogerio Vivaldi, M.D. EVP and chief global therapeutic operations officer, and John T. Greene, EVP and chief financial officer

UPDATE 3-Ionis, Biogen drug for fatal infant disorder succeeds in key study

* Drug may get $1 bln-$2 bln in peak annual sales - Piper Jaffray

BRIEF-Biogen and Ionis Pharmaceuticals announce SPINRAZA meets primary endpoint at interim analysis of phase 3 cherish study

* Biogen and Ionis Pharmaceuticals announce SPINRAZA (nusinersen) meets primary endpoint at interim analysis of phase 3 cherish study in later-onset spinal muscular atrophy

Ionis and Biogen's muscular disorder treatment meets main goal

Nov 7 Biogen Inc and Ionis Pharmaceuticals said their investigational treatment for a type of rare genetic muscular disorder met its main goal in an interim analysis of a late-stage study.

BRIEF-Biogen's regulatory applications for nusinersen as a treatment for spinal muscular atrophy accepted by FDA, EMA

* Biogen's regulatory applications for nusinersen as a treatment for spinal muscular atrophy accepted by FDA and EMA

Biogen profit tops expectations; focus on CEO search, new drugs

Biogen Inc on Wednesday reported better-than-expected third quarter profit, driven by higher sales of its lead multiple sclerosis drug and lower costs, and its shares rose more than 4 percent.

BRIEF-Biogen CEO says search to find successor progressing

* Says expects reimbursement for new MS drug Zinbryta throughout Europe within 12-18 months

Drugmaker Biogen quarterly profit rises 7 pct

Oct 26 Biogen Inc reported a 7 percent rise in quarterly profit, helped by higher sales of its multiple sclerosis drugs.

BRIEF-Anavex signs material transfer agreement with Biogen

* Signed material transfer agreement with Biogen under which Biogen will test Anavex's lead drug candidate, Anavex 2-73 Source text for Eikon: Further company coverage:

Select another date: